#United States #Boston #LEP #Burmese #RxTran

Surge in Burmese Prescription Translation Demand: A New Trend in U.S. Pharmacy Care

Recent data from RxTran indicates a remarkable shift in the demand for Burmese-language prescription translation services, which skyrocketed by over 300% from the first quarter of 2025 to the first quarter of 2026. This spike reveals a significant transformation in how U.S. pharmacies cater to patients with Limited English Proficiency (LEP), particularly those from Asian and Middle Eastern backgrounds.

Overview of the Findings

According to the report, the demand for Burmese prescription labels reflects broader trends among diverse immigrant populations. While requests for several major European languages have seen a decline, the demand for languages such as Pashto (up 60%), Farsi (up 52%), and Vietnamese (up 49%) has also increased significantly during the same timeframe. This shift aligns with U.S. Census Bureau statistics that highlight growth in South and Southeast Asian and Middle Eastern communities within the United States.

Implications for Pharmacy Care

The implications of these findings extend far beyond mere statistics; they carry direct consequences for pharmacy compliance and patient safety. Language barriers often lead to patient non-adherence to prescription guidelines, which, according to estimates, accounts for around 22% of all hospitalizations annually across the country. Federal regulations, including Title VI of the Civil Rights Act and Section 1557 of the Affordable Care Act, mandate that healthcare providers receiving federal funding must offer language access services to LEP patients.

Increasingly, states are implementing pharmacy-specific requirements for translation services, further emphasizing the need for pharmacies to evolve in their practices.

A Call to Action

As Sharon Blank, CEO of Language Scientific and RxTran, stated, “These trends reflect the communities pharmacies serve today.” The expanding and diversifying LEP population in the U.S. signals a need for pharmacies to move away from static language coverage, as failing to do so could expose them to compliance risks and neglect vulnerable patient groups.

Pharmacies are urged to leverage RxTran’s insights to identify gaps in language coverage proactively, ensuring that no patient is left at risk due to inadequate communication.

Innovative Solutions with RxTran

RxTran’s revolutionary Transduction technology offers a robust platform for addressing these challenges. The system processes prescription SIG translations across 26 languages, integrating seamlessly with major national pharmacy management systems. This ensures that translated labels are delivered at the point of dispensing, fully compliant with regulatory requirements. RxTran's technology, protected by U.S. Patent No. 11,836,454 and various pending applications, contributes to the creation of a safer, more inclusive pharmacy environment.

Conclusion

The recent data from RxTran, which is part of an ongoing series launched in August 2024, underscores the critical need for enhanced language access in U.S. pharmacy care. As the demand for Burmese and other non-European language translations rises, pharmacies must adapt to support their diverse patient bases effectively. By doing so, they not only fulfill legal obligations but also improve overall patient health outcomes and satisfaction. Investing in language access capabilities is no longer just an option; it is a necessity for modern pharmacy practices.